Tumori Genitourinari Nuove prospettive
Roberto Iacovelli
UOC di Oncologica Medica
AIOM Post ESMO 2019
Disclosures
Dichiaro che negli ultimi due anni ho avuto i seguenti rapporti anche di finanziamento con soggetti portatori di interessi commerciali in campo sanitario:
• Ipsen
• Janssen
• MSD
• Novartis
• Pfizer
• Sanofi
Agenda
• The intensification strategy: the TITAN trial
• Management of patients with sRCC
• Sequence in mCRPC
• Olaparib in mCRPC, the new option for DRD patients.
• Atezolizumab ± Chemioterapia nella I linea per neoplasia vescicale
Agenda
• The intensification strategy: the TITAN trial
• Management of patients with sRCC
• Sequence in mCRPC
• Olaparib in mCRPC, the new option for DRD patients.
• Atezolizumab ± Chemioterapia nella I linea per neoplasia vescicale
The intensification strategy: the TITAN trial
The intensification strategy: the TITAN trial
The intensification strategy: the TITAN trial
The intensification strategy: the TITAN trial
The intensification strategy: the TITAN trial
The intensification strategy: the TITAN trial
Agenda
• The intensification strategy: the TITAN trial
• Management of patients with sRCC
• Sequence in mCRPC
• Olaparib in mCRPC, the new option for DRD patients.
• Atezolizumab ± Chemioterapia nella I linea per neoplasia vescicale
Avelumab+Axitinib in patients with sarcomatoid features
Choueiri TK et al, ESMO 2019 Poster 910 PD
Management of patients with sarcomatoid mRCC
De Velasco ESMO 2019
Agenda
• The intensification strategy: the TITAN trial
• Management of patients with sRCC
• Sequence in mCRPC
• Olaparib in mCRPC, the new option for DRD patients.
• Atezolizumab ± Chemioterapia nella I linea per neoplasia vescicale
Lo studio CARD
Lo studio CARD
Cabazitaxel (N = 129) ART (N = 126) Median age, years (range)
≥ 75 years, n (%)
70.0 (46–85) 45 (34.9)
71.0 (45–88) 34 (27.0)
ECOG PS 0–1, n (%) 123 (95.3) 119 (94.4)
Visceral metastases, n (%) 21 (16.3) 25 (19.8)
Type of progression at study entry, n (%) PSA only
Radiologic (± PSA), no pain Pain (± PSA, ± radiologic) Missing
11 (8.5) 23 (17.8) 86 (66.7)
9 (7.0)
10 (7.9) 16 (12.7) 90 (71.4) 10 (7.9)
Gleason 8–10 at diagnosis, n (%) 73 (56.6) 81 (64.3)
M1 disease at diagnosis, n (%) 49 (38.0) 60 (47.6)
Prior ART, n (%)
Abiraterone / enzalutamide Before / after docetaxel
56 (43.4) / 72 (55.8) 50 (38.8) / 79 (61.2)
67 (53.2) / 59 (46.8) 49 (38.9) / 77 (61.1)
Lo studio CARD
Lo studio CARD
Lo studio CARD
Agenda
• The intensification strategy: the TITAN trial
• Management of patients with sRCC
• Sequence in mCRPC
• Olaparib in mCRPC, the new option for DRD patients.
• Atezolizumab ± Chemioterapia nella I linea per neoplasia vescicale
Prostate cancer: the PROFOUND trial
Prostate cancer: the PROFOUND trial
Prostate cancer: the PROFOUND trial
Prostate cancer: the PROFOUND trial
Prostate cancer: the PROFOUND trial
Prostate cancer: the PROFOUND trial
Agenda
• The intensification strategy: the TITAN trial
• Management of patients with sRCC
• Sequence in mCRPC
• Olaparib in mCRPC, the new option for DRD patients.
• Atezolizumab ± Chemioterapia nella I linea per neoplasia vescicale
